Tag: Indivior PLC

Hansa Biopharma announces key executive appointments to support continued growth

LUND, Sweden, July 29, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced three leadership appointments. Brian Gorman joins Hansa as...

Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained

SLOUGH, United Kingdom and RICHMOND, Va., July 25, 2025 /PRNewswire/ -- Further to the announcement made on June 2, 2025, Indivior PLC (Nasdaq: INDV)...

Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid...

Extended-release buprenorphine (BUP-XR) had lower rates of hospitalizations, emergency department (ED) visits, and outpatient physician oﬃce visits compared to those receiving daily oral buprenorphine or no medications for...

Indivior Appoints Tony Kingsley to the Board of Directors

RICHMOND, Va., June 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Tony Kingsley to the Board of...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Comments

This field is for validation purposes and should be left unchanged.

HomeTagsIndivior PLC

Sony Semiconductor Solutions to Release X-ray CMOS Sensor with Industry’s Fastest(*1) Imaging and Low-Noise Performance for Inspection and Measurement Instrumentation

Antaisolar Showcases Upgraded 2P Tracker Solution at SNEC 2026, Securing Multiple Global Partnerships

APOTEX HEALTH CORP. UPSIZES ITS INITIAL PUBLIC OFFERING

Tag: Indivior PLC

Hansa Biopharma announces key executive appointments to support continued growth

Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained

Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid...

Indivior Appoints Tony Kingsley to the Board of Directors

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us